Needham analyst Ami Fadia maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) today and set a price target of $133.00.Don't ...

M&A didn’t return as hoped for in 2024. The biopharma industry is heading into the J.P. Morgan Healthcare Conference next week in a grim mood.

The company recently announced results from two Phase 3 trials of AXS-05 for agitation. ACCORD-2, hit its main goal, but ...

In one study, the company’s drug eased the agitation for Alzheimer’s patients. In a different study, there wasn’t a ...

Sangamo shares fell on Pfizer’s decision to hand back rights to a hemophilia gene therapy. Elsewhere, Novartis got ...

With two earlier trials meeting their primary endpoints, Axsome claimed it has the data to support a filing for FDA approval ...

Axsome Therapeutics, Inc. (NASDAQ:AXSM) released data from ACCORD-2, ADVANCE-2, and long-term safety trials AXS-05 ...

Axsome Therapeutics shows strong revenue growth with promising pipeline drugs for migraine, fibromyalgia, and narcolepsy.

US CNS specialist Axsome Therapeutics yesterday announced the completion of its Phase III clinical program evaluating AXS-05 ...

H.C. Wainwright analyst Ram Selvaraju has reiterated their bullish stance on AXSM stock, giving a Buy rating yesterday.Don't Miss Our New ...

The Scientist explored the work of a researcher who had an unexpected finding while developing a novel anti-tau therapy.